PHS
VRTX icon

PFM Health Sciences’s Vertex Pharmaceuticals VRTX Stock Holding History

PFM Health Sciences’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-126,200
Closed -$27.6M – 77
2019
Q4 		$27.6M Buy
+126,200
New +$25.5M 1.32% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PFM Health Sciences's VRTX Position: Q2 2025 in Review

PFM Health Sciences sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 126,989 shares — an estimated $61.6M sold.

PFM Health Sciences first reported a position in VRTX in Q2 2016 and held it in 11 quarters. The position peaked at $69.8M in Q2 2024. 1,560 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • PFM Health Sciences reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • PFM Health Sciences sold 126,989 Vertex Pharmaceuticals shares in Q2 2025, an estimated $61.6M.
  • PFM Health Sciences first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 11 quarters.
  • PFM Health Sciences's Vertex Pharmaceuticals position peaked at $69.8M in Q2 2024.
  • 1,560 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.